Zhang W, Chen L, Xiang H, Hu C, Shi W, Dong P, et al
Regarding safety profile, in phase 2 trials for obesity and diabetes, mazdutide was discontinued due to AE by 02% of participants and SAE experienced by up to 7% of participants with mazdutide 6 mg (Tables 2 and 3)
By exploring GLP-1, individuals can gain insights into their body's natural mechanisms for weight control
FDA noted in the warning letter that [i]t is unacceptable as a matter of CGMP to continue manufacturing drugs using the same equipment that you use to manufacture pesticides or other non-pharmaceutical products due to the risk of cross-contamination. 35 FDA also found that the active ingredient isopropanol was substituted wholly or in part with ethanol and cited the company for inadequate release testing, among other violations
While this approach allowed us to include all available subjects, it limits interpretation of potential sex-specific effects